Dr. Oz’s GLP-1 Bridge Could Work, But It Isn’t a Model for Price Controls
Dr Oz s GLP 1 Bridge – Earlier this year, Dr. Mehmet Oz introduced a new initiative under the Centers for Medicare and Medicaid Services, offering eligible Medicare Part D beneficiaries access to selected GLP-1 obesity medications at a reduced cost of $50 per month, beginning July 1. This temporary program, dubbed the Medicare GLP-1 Bridge, will remain in effect until the end of 2027. It includes drugs like Wegovy, Zepbound, and Foundayo, provided they are used specifically for weight management purposes.
For elderly individuals and those with chronic disabilities battling obesity and its associated health complications, the Bridge program presents a significant opportunity. Obesity is recognized as a debilitating, long-term condition that increases the likelihood of diabetes, heart disease, and sleep apnea—among other expensive health issues. Patients shouldn’t be denied access to innovative treatments simply because Medicare’s existing policies haven’t adapted to the rapid advancements in pharmaceuticals.
“Patients should not be locked out of modern treatments simply because Medicare rules have not kept up with the rapid pace of innovation,”
asserts the article, highlighting the urgency of expanding access to effective obesity medications. However, the program’s $50 monthly rate is not a reflection of the drugs’ inherent market value. Instead, it represents a strategic subsidy designed to provide immediate relief to beneficiaries while the broader healthcare system adjusts.
The Bridge operates independently of the standard Part D payment structure, creating a unique pathway for coverage. Pharmacies will charge patients the $50 copay, while a central processor will manage reimbursements to the pharmacies. Manufacturers, in turn, will supply eligible GLP-1 drugs at a net price of $245 per month, effectively subsidizing the cost for patients. This arrangement shifts the financial burden to taxpayers, who are funding the program as a pilot effort to test affordability.
The Program’s Structure and Implications
At its core, the Bridge program functions as a short-term financial intervention, allowing patients to benefit from lower out-of-pocket costs without altering the existing pricing dynamics of the pharmaceutical market. While the $50 copay appears favorable, it’s important to note that this is not a permanent solution. The program is a targeted effort to evaluate how subsidies can alleviate the burden of high drug prices for a specific group of beneficiaries.
Yet, the program’s success hinges on the assumption that the $50 rate is a sustainable model for price control. Critics argue that this approach risks setting a precedent where government intervention becomes the standard for determining drug costs. If policymakers interpret the Bridge as evidence that the federal government can unilaterally set prices, the long-term consequences could be profound. For instance, it might deter pharmaceutical companies from investing in future breakthroughs, as they could anticipate lower returns due to government mandates.
Competition and direct access to medications are key drivers of cost reduction in the drug market. The Bridge program capitalizes on these forces, as manufacturers have already begun adjusting prices in response to consumer demand. In 2024, Lilly introduced Zepbound through a self-pay channel at $399 for the 2.5 mg dose and $549 for the 5 mg dose, bypassing traditional supply chains to offer lower prices. By the end of 2025, consumer prices had dropped by up to 27 percent, demonstrating the market’s ability to self-correct when given the right incentives.
Market Forces and the Path to Affordability
Similarly, NovoCare Pharmacy has experimented with direct-to-consumer pricing for Wegovy, initially offering it at $499 per month for cash-paying patients. Subsequent discounts brought the price down to $199 for the first two fills, then $349 for subsequent months. These examples underscore the role of competition and consumer choice in reducing drug costs. When patients can access medications directly, without relying on insurers or government programs, manufacturers are compelled to adjust their pricing strategies.
The Bridge program, therefore, is not a standalone model for price controls but rather a reflection of the broader trend toward market-driven affordability. By allowing Medicare beneficiaries to use the program, policymakers are testing whether subsidies can create a pathway for access without permanently fixing drug prices. The initiative highlights the importance of maintaining a balance between affordability and innovation, ensuring that patients receive necessary treatments while preserving incentives for pharmaceutical development.
However, the danger lies in the interpretation of the program. If the government begins using the Bridge as a justification for permanent price-setting, it could disrupt the market’s natural equilibrium. Most-Favored-Nation (MFN) pricing, which aims to mirror international drug costs, has been a recurring topic in policy debates. While it promises lower prices, it also introduces foreign price controls into the U.S. system, potentially limiting the flexibility of domestic markets.
The MFN model, as described by CMS, requires drug manufacturers to charge no more than the lowest prices available in developed countries. While this may seem like a straightforward solution, it risks creating a scenario where American consumers are locked into a pricing structure that may not account for local healthcare needs or innovation costs. If the government institutionalizes this model, it could lead to a reduction in investment for new treatments, as companies might perceive the U.S. market as less profitable.
Consumers will benefit from today’s affordability only if tomorrow’s breakthroughs are not compromised. The Bridge program serves as a temporary measure to address immediate access issues, but it should not become a blueprint for long-term price controls. By keeping the initiative as a trial, policymakers can assess its effectiveness while preserving the dynamic nature of the pharmaceutical market.
Ultimately, the Medicare GLP-1 Bridge is a valuable experiment in expanding access for those in need. It provides a model for how subsidies can be used to lower costs for specific populations without overreaching into broader price regulation. The administration should ensure that the program is seen as a transitional solution rather than a permanent shift in how drug pricing is managed. This approach allows for continued innovation and competition, which are essential to maintaining affordable healthcare options for all Americans.
Fred Roeder, a health economist and director of the Consumer Choice Center, emphasizes the importance of preserving market mechanisms in healthcare. His insights provide a critical perspective on the role of subsidies and the potential pitfalls of government price-setting. By aligning the Bridge program with these principles, policymakers can strike a balance that supports both affordability and innovation.
